Clinical Risk Assessments Considerations for Immunogenicity & Tolerogenicity for LNP Vectored Therapeutics Vaccine

Time: 9:00 am
day: Day One


  • Evaluating the potential for the LNP vector to induce antigen-presenting cells that may trigger unwanted immune responses
  • Analyzing the likelihood of the vaccine inducing the production of antibodies against the therapeutic antigen
  • Understanding the persistence of the tolerogenic response induced by the LNP-based vaccine over time